Clinical Trials in Egypt / NCT07239024
Enrolling by invitation
Phase 1
Evaluation of Piezocision Versus Injectable Platelet-rich Fibrin During Orthodontic Canine Retraction Orthodontic Canine Retraction: A Comparative Clinical Study
NCT07239024 · tracked via the Priya Life Science Egypt tracker
Condition(s) studied
Effect of Piezocision and Injectable Platelets Rich Fibrin on Tooth Movement
Investigational drug(s) / intervention(s)
Iprf and piezocision
Iprf and piezocision: Injection of iprf and piezocisin
Study summary
Comparison of piezocisin and injectable platelets rich fibrin during canine retraction
Eligibility
Inclusion Criteria:. An age ranges from 14-22 years. 2. Crowding or protrusion that require 1st premolars extraction, followed by symmetrical canine retractions.
3\. All permanent teeth present, 3rd molars aren't considered. 4. Good oral hygiene. 5. No systemic disease and/or medication that could interfere with orthodontic tooth movement. 6. No previous orthodontic treatment. 7. No evidence of craniofacial anomalies, such as cleft lip and palate or previous history of trauma, bruxism, or parafunction. 8. No tooth size, shape, or root abnormalities visible on patient's radiographic records.
\-
Exclusion Criteria:Patients diagnosed to have an indication for non-extraction approach.
2\. Poor oral hygiene or periodontally compromised patient.
* 3\. Previous orthodontic treatment. 4. Any implanted assistive (e.g., pacemakers, cochlear implants, etc.). 5. Any skeletal dysplasia or craniofacial malformation. 6. Patients with root resorption, impacted canine or dental anomalies. 7. Any systemic diseases or medications that could interfere with orthodontic tooth movement.
Primary outcome measure(s)
- Rate of canine retraction — 4 months
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| AlAzhar university | Cairo | Egypt |
More Al-Azhar University trials in Egypt
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07239024 on ClinicalTrials.gov ↗ ← All trials in Egypt